C14 Ceramide (d18:1/14:0)
(Synonyms: 十四酰鞘氨醇,Cer(d18:1/14:0)) 目录号 : GC43022
A bioactive sphingolipid
Cas No.:34227-72-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
C14 Ceramide is an endogenous ceramide generated by ceramide synthase 6. [1] During nutrient-deprivation-induced necroptosis in MEF cells, C14 ceramide levels increase in a time-dependent manner. [2] C14 ceramide plasma levels were reduced in obese patients with or without diabetes following a 12-week supervised exercise training program, correlating positively with weight and fat loss and negatively with an increase in insulin sensitivity. [3] In contrast, plasma levels were higher in Parkinson's disease patients with dementia than those without dementia and higher levels were correlated with deficits in memory.[4]
Reference:
[1]. Grosch, S., Schiffmann, S., and Geisslinger, G. Chain length-specific properties of ceramides. Prog. Lipid Res. 51(1), 50-62 (2012).
[2]. Sundaram, K., Mather, A.R., Marimuthu, S., et al. Loss of neutral ceramidase protects cells from nutrient- and energy -deprivation-induced cell death. Biochem J. 473(6), 43-55 (2016).
[3]. Kasumov, T., Solomon, T.P., Hwang, C., et al. Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. Obesity (Silver Spring) 23(7), 1414-1421 (2015).
[4]. Xing, Y., Tang, Y., Zhao, L., et al. Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson’s disease dementia. J. Neurol. Sci. 370, 82-87 (2016).
| Cas No. | 34227-72-0 | SDF | |
| 别名 | 十四酰鞘氨醇,Cer(d18:1/14:0) | ||
| 化学名 | N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-tetradecanamide | ||
| Canonical SMILES | OC[C@H](NC(CCCCCCCCCCCCC)=O)[C@H](O)/C=C/CCCCCCCCCCCCC | ||
| 分子式 | C32H63NO3 | 分子量 | 509.9 |
| 溶解度 | DMF: 0.15 mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9612 mL | 9.8058 mL | 19.6117 mL |
| 5 mM | 0.3922 mL | 1.9612 mL | 3.9223 mL |
| 10 mM | 0.1961 mL | 0.9806 mL | 1.9612 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。